Related Experiment Videos
Is antithyroid treatment really relevant for young patients with subclinical hyperthyroidism?
Ozlem Yönem1, Hatice Sebila Dökmetaş, Süleyman Murat Aslan
1Department of Internal Medicine, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey.
Endocrine Journal
|August 31, 2002
Summary
Subclinical hyperthyroidism (SCH) can cause symptoms like fatigue and nervousness, which may improve with treatment. However, treatment did not show benefits for bone mineral density or heart health in young patients.
Area of Science:
- Endocrinology
- Internal Medicine
Background:
- Subclinical hyperthyroidism (SCH) is a condition with low thyroid-stimulating hormone (TSH) levels but normal free thyroid hormone levels.
- The presence and impact of SCH symptoms, and the effects of treatment on bone mineral density (BMD) and cardiovascular parameters, remain areas of investigation.
Purpose of the Study:
- To investigate the presence of hyperthyroid symptoms and findings in patients with SCH.
- To determine if antithyroid treatment improves these symptoms and affects BMD, blood pressure, and serum lipids.
Main Methods:
- A study included 20 patients with SCH and 20 healthy controls.
- Patients were randomized into a treatment group (achieving euthyroidism) and an observation group.
- Evaluations included BMD, 24-hour ambulatory blood pressure, Holter monitoring, and serum lipids before and after 6 months.
Main Results:
- BMD did not differ significantly between SCH patients and controls, despite slight decreases in the patient group.
- Symptoms such as fatigue, nervousness, sweating, and tachycardia improved with antithyroid treatment.
- In the observation group, these symptoms increased over the 6-month follow-up.
- No significant improvements were observed in BMD, serum lipids, heart rate, or arrhythmia incidence in either group after 6 months.
Conclusions:
- Hyperthyroid symptoms can manifest in SCH and may partially resolve with treatment.
- Antithyroid treatment did not demonstrate favorable effects on BMD, heart rate, or arrhythmia incidence in young, premenopausal SCH patients within a 6-month period.